DE10119946A1 - Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance - Google Patents

Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance

Info

Publication number
DE10119946A1
DE10119946A1 DE10119946A DE10119946A DE10119946A1 DE 10119946 A1 DE10119946 A1 DE 10119946A1 DE 10119946 A DE10119946 A DE 10119946A DE 10119946 A DE10119946 A DE 10119946A DE 10119946 A1 DE10119946 A1 DE 10119946A1
Authority
DE
Germany
Prior art keywords
increasing
carnitine
creatine
effervescent tablet
addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10119946A
Other languages
German (de)
Inventor
Joachim Steuer
Michaela Steuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE10119946A priority Critical patent/DE10119946A1/en
Publication of DE10119946A1 publication Critical patent/DE10119946A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet is new.

Description

Die Erfindung betrifft eine Zugabe zu einer an sich üblichen Brausetablette. Die Zugabe hat einen Gehalt an mindestens einem der folgenden Bestandteile: CLA (konjungierte Linolsäure), L-Carnitin, Kreatin. The invention relates to an addition to a conventional effervescent tablet. The addition contains at least one of the following components: CLA (conjugated linoleic acid), L-carnitine, creatine.

Die Brausetablette ist dadurch gekennzeichnet, daß sie mindestens einen der folgenden Zusatzstoffe enthält: CLA (konjungierte Linolsäure), L-Carnitin, Kreatin. The effervescent tablet is characterized in that it has at least one of the following Additives contains: CLA (conjugated linoleic acid), L-carnitine, creatine.

Im Gegensatz zu den bisherigen bekannten Darreichungsformen als z. B. Tabletten werden CLA und/oder L-Carnitin und/oder Kreatin als Zusatz zu einer Brausetablette dargereicht. In contrast to the previously known dosage forms as z. B. tablets are CLA and / or L-carnitine and / or creatine as an addition to an effervescent tablet presented.

Angabe der Wirkungen, die mit der Erfindung erzielt werden sollenIndication of the effects to be achieved with the invention

Die oben genannten Inhaltsstoffe besitzen mindestens eine der folgenden Eigenschaften:

  • - Steigerung der Proteinsynthese im Muskel
  • - Steigerung der Fettverbrennung
  • - Steigerung der Leistungsfähigkeit
  • - Steigerung des Aufbaues fettfreier Muskelmasse
  • - Förderung der körpereigenen Energieproduktion
  • - Verbesserung der Vitalität
  • - Normalisierung des Stoffwechsels
  • - Einfluß auf den Energiestoffwechsel der Skelettmuskulatur
  • - Einfluß auf schnellere kurzzeitig Regenerierung von ATP-Vorräten
The above ingredients have at least one of the following properties:
  • - Increased protein synthesis in the muscle
  • - Increase fat burning
  • - Increase in performance
  • - Increase in building lean muscle mass
  • - Promotion of the body's energy production
  • - Improve vitality
  • - normalization of metabolism
  • - Influence on the energy metabolism of the skeletal muscles
  • - Influence on faster short-term regeneration of ATP stocks

Die vorliegende Erfindung hat das Ziel, eine schneller resorbierbare und magenfreundliche Dareichung von CLA und/oder L-Carnitin und/oder Kreatin zu Darreichung von CLA und/oder L-Carnitin und/oder Kreatin in Tablettenform erzielen. Bei der Darreichung verzögert sich die erwünschte Wirkung dadurch, daß die Tablette sich erst im Magen auflösen muß. Als Bestandteil einer Brausetablette kommen CLA und/oder L-Carnitin und/oder Kreatin aber erheblich schneller zur Wirkung und sind erheblich magenfreundlicher, da die Magensäfte die Tablette nicht erst auflösen müssen. Eine zusätzliche Zufuhr von CLA und/oder L-Carnitin und/oder Kreatin ist sinnvoll, um Defizite bei starken körperlichen Anstrengungen auszugleichen und die körperliche Leistungsfähigkeit zu steigern. The present invention aims to provide a more absorbable and stomach-friendly administration of CLA and / or L-carnitine and / or creatine Administration of CLA and / or L-carnitine and / or creatine in tablet form achieve. When administered, the desired effect is delayed in that the The tablet first has to dissolve in the stomach. As part of an effervescent tablet CLA and / or L-carnitine and / or creatine come much faster Effect and are considerably more stomach-friendly since the gastric juices do not affect the tablet have to dissolve first. An additional supply of CLA and / or L-carnitine and / or Creatine is useful to compensate for deficits during heavy physical exertion and increase physical performance.

Die erfindungsgemäßen Zugaben zu einer Brausetablette sind:
CLA
L-Carnitin
Kreatin The additions to an effervescent tablet according to the invention are:
CLA
L-carnitine
creatine

Es können ein oder mehrere der genannten Bestandteile enthalten sein. Der Schutz soll Gültigkeit haben, wenn mindestens einer der oben genannten Inhaltsstoffe als Zusatz beigegeben wird. One or more of the ingredients mentioned can be included. The protection should be valid if at least one of the above Ingredients are added as an additive.

Claims (1)

Die Zugabe von CLA (konjugierte Linolsäure) und/oder Kreatin und/oder L-Carnitin zu einer an sich üblichen Brausetablette. The addition of CLA (conjugated linoleic acid) and / or creatine and / or L-carnitine to a usual effervescent tablet.
DE10119946A 2001-04-24 2001-04-24 Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance Withdrawn DE10119946A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE10119946A DE10119946A1 (en) 2001-04-24 2001-04-24 Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10119946A DE10119946A1 (en) 2001-04-24 2001-04-24 Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance

Publications (1)

Publication Number Publication Date
DE10119946A1 true DE10119946A1 (en) 2003-04-30

Family

ID=7682463

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10119946A Withdrawn DE10119946A1 (en) 2001-04-24 2001-04-24 Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance

Country Status (1)

Country Link
DE (1) DE10119946A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113540A2 (en) * 2006-04-05 2007-10-11 The University Of Nottingham Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling garnitine content in muscle
DE102007009649A1 (en) * 2007-02-26 2008-08-28 Beiersdorf Ag Food supplement for cosmetic care and treatment of the skin, contains at least two cosmetically-active substances, especially conjugated linoleic acid, L-carnitine or its derivatives and-or mate tea extract
WO2011072320A1 (en) * 2009-12-14 2011-06-23 Jubilent Global Limited Effervescent l-carnitine-based composition
CN114343170A (en) * 2021-12-30 2022-04-15 北京康比特体育科技股份有限公司 Effervescent tablet containing creatine and preparation method thereof
EP4027990A4 (en) * 2019-10-16 2023-10-18 Capsugel Belgium NV Method and composition for increasing muscle protein synthesis
EP4027991A4 (en) * 2019-10-16 2023-11-22 Capsugel Belgium NV Method and composition for increasing muscle protein synthesis

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113540A2 (en) * 2006-04-05 2007-10-11 The University Of Nottingham Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling garnitine content in muscle
WO2007113540A3 (en) * 2006-04-05 2008-03-13 Univ Nottingham Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling carnitine content in muscle
DE102007009649A1 (en) * 2007-02-26 2008-08-28 Beiersdorf Ag Food supplement for cosmetic care and treatment of the skin, contains at least two cosmetically-active substances, especially conjugated linoleic acid, L-carnitine or its derivatives and-or mate tea extract
WO2008104270A2 (en) * 2007-02-26 2008-09-04 Beiersdorf Ag Food supplements for looking after and/or improving the appearance of the skin
WO2008104270A3 (en) * 2007-02-26 2009-11-26 Beiersdorf Ag Food supplements for looking after and/or improving the appearance of the skin
WO2011072320A1 (en) * 2009-12-14 2011-06-23 Jubilent Global Limited Effervescent l-carnitine-based composition
AU2009356961B2 (en) * 2009-12-14 2016-05-19 Jubilent Global Limited Effervescent L-carnitine-based composition
EP4027990A4 (en) * 2019-10-16 2023-10-18 Capsugel Belgium NV Method and composition for increasing muscle protein synthesis
EP4027991A4 (en) * 2019-10-16 2023-11-22 Capsugel Belgium NV Method and composition for increasing muscle protein synthesis
CN114343170A (en) * 2021-12-30 2022-04-15 北京康比特体育科技股份有限公司 Effervescent tablet containing creatine and preparation method thereof

Similar Documents

Publication Publication Date Title
EP0874618B1 (en) Preparation for improving hair growth, the skin structure and/or nail regeneration
DE3213284A1 (en) ANTI-CARIES CHEWING GUM
WO2003016544A1 (en) Process for producing 1,4-dihydroxy-2-naphthoic acid
HRP20120228T1 (en) Cladribine regimen for treating multiple sclerosis
DE2128461A1 (en) Pharmaceutical preparation
EP0037488B1 (en) Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
DE10119946A1 (en) Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance
DE1767017A1 (en) Iron preparation
DE2305980A1 (en) MINERAL SALT PREPARATION
DE60004204T2 (en) PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE ORAL ADMINISTRATION OF PHLOROGLUCINOL AND THE PRODUCTION THEREOF
DE1667887B1 (en) Aminosaeurelösungen for parenteral infusion
DE3421644C2 (en)
WO1996033707A1 (en) Topical preparation for promoting muscular development
DE3632791A1 (en) AGENT AGAINST AGE CHANGES
CA2305764A1 (en) Bile acid salts of metals with physiological action and the use thereof in therapy
DE2523394A1 (en) PHARMACEUTICAL PREPARATION
EP0340540A2 (en) Agent for the prophylaxis of a heart infarct and for the prevention of another infarct
DE19922932B4 (en) Cosmetic preparation and process for its preparation
WO2007031291A2 (en) Foodstuff additive
DE2117852A1 (en) Retarded release tablet and process for its manufacture
DE60121142T2 (en) COMPOSITION COMPRISING PARACETAMOL AND NIFLUMIC ACID CONTENT
DE3225491A1 (en) PHARMACEUTICAL COMPOSITION, ITS PRODUCTION AND USE
DE375482C (en) Surgical aids that are used for introduction into the human body, especially into the tissues
DE2635293A1 (en) SALT MIXTURE, IN PARTICULAR EASILY ASSIMILABLE MEDICINAL MIXTURE WITH INCREASED SOLUBILITY, CONTAINS CALCIUM SALTS AND / OR MAGNESIUM SALTS

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee